ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Apalutamide (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS
- Sponsors Aragon Pharmaceuticals; Janssen-Cilag
- 07 Mar 2017 Planned End Date changed from 1 Oct 2026 to 6 Oct 2026.
- 07 Mar 2017 Planned primary completion date changed from 1 Dec 2022 to 30 Dec 2022.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.